Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

141. Incidence of Dementia over Three Decades in the Framingham Heart Study.

Incidence of Dementia over Three Decades in the Framingham Heart Study. Incidence of Dementia over Three Decades in the Framingham Heart Study. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406364 Format (...) MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):93. doi: 10.1056/NEJMc1604823#SA2. Incidence of Dementia over Three Decades in the Framingham Heart Study. 1 , 1 , 2 . 1 Medical Research Society, Vienna, Austria margareta.hinterberger@utanet.at. 2 Medical University of Vienna, Vienna, Austria. Comment in [N Engl J Med

NEJM2016 Full Text: Link to full Text with Trip Pro

142. The International Dementia Alliance Instrument for Feasible and Valid Staging of Individuals with Dementia by Informal Caregivers

The International Dementia Alliance Instrument for Feasible and Valid Staging of Individuals with Dementia by Informal Caregivers 27304200 2016 08 17 2016 08 17 1532-5415 64 8 2016 Aug Journal of the American Geriatrics Society J Am Geriatr Soc The International Dementia Alliance Instrument for Feasible and Valid Staging of Individuals with Dementia by Informal Caregivers. 1674-8 10.1111/jgs.14205 To assess the feasibility and validity of the International Dementia Alliance (IDEAL) instrument (...) for Informal Caregivers (IDEAL-IC), which is based on the IDEAL instrument for professionals (IDEAL-P), for staging individuals with dementia. Cross-sectional. Memory clinic of a university hospital. Informal caregivers of 73 community-dwelling elderly adults referred to a memory clinic and six geriatric registrars. Caregivers completed the IDEAL-IC; physicians completed the original IDEAL-P and the Clinical Dementia Rating sum of boxes (CDR-SB). Missing items and floor and ceiling effects were reviewed

EvidenceUpdates2016

143. Treatment for Dementia: Learning from Breakthroughs for Other Conditions

Treatment for Dementia: Learning from Breakthroughs for Other Conditions 28083433 2017 08 16 2162-8254 6 1 2016 Jun 20 Rand health quarterly Rand Health Q Treatment for Dementia: Learning from Breakthroughs for Other Conditions. 5 The past few decades have seen a number of medical breakthroughs that enabled the effective treatment of a range of conditions, transforming them from fatal into manageable ones. Examples include certain cancers and HIV. Conversely, progress on dementia has been (...) limited. There are currently no treatments that will cure or even alter the progressive course of dementia, despite ongoing research investigating new therapies and care options. The UK Department of Health is interested in the potential to learn from other disease areas to better understand the particular social, economic, political, legislative and scientific contexts that have contributed to accelerating progress and breakthroughs in treatment. Such learning could helpfully inform dementia research

Rand health quarterly2016 Full Text: Link to full Text with Trip Pro

144. Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia

Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia 27073239 2016 04 26 2017 05 10 2017 05 10 1524-4628 47 5 2016 May Stroke Stroke Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia. 1201-6 10.1161/STROKEAHA.115.012608 The American Heart Association developed the ideal cardiovascular health (CVH) index as a simple tool to promote CVH; yet, its association with brain atrophy and dementia remains unexamined. Our aim (...) was to investigate the prospective association of ideal CVH with vascular brain injury, including the 10-year risks of incident stroke and dementia, as well as cognitive decline and brain atrophy on magnetic resonance imaging, measured for ≈7 years. We studied 2750 stroke- and dementia-free Framingham Heart Study Offspring cohort participants (mean age, 62±9 years; 45% men). Ideal CVH was quantified on a 7-point scale with 1 point awarded for each of the following: nonsmoking status, ideal body mass index

EvidenceUpdates2016

145. Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study

Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study 27398296 2018 11 13 2199-1154 3 2 2016 Jun Drugs - real world outcomes Drugs Real World Outcomes Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. 175-182 Antipsychotics are commonly used to manage behavioral and psychological symptoms of dementia. Concerns over their safety and efficacy in this role have resulted (...) in antipsychotics typically being recommended for short-term usage only when used among dementia patients. However, there is little work examining the duration of antipsychotic treatment in the elderly dementia patient population. To determine the persistence of use of antipsychotics in elderly dementia patients and the role of dose on therapy duration. A retrospective, population-based cohort study using administrative data, including dispensing records from a provincial public drug program, from Ontario

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

146. Nonpharmacologic interventions for agitation and aggression in dementia

Nonpharmacologic interventions for agitation and aggression in dementia Nonpharmacologic interventions for agitation and aggression in dementia Nonpharmacologic interventions for agitation and aggression in dementia Brasure M, Jutkowitz E, Fuchs E, Nelson VA, Kane RA, Shippee T, Fink HA, Sylvanus T, Ouellette J, Butler M, Kane RL Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Brasure M, Jutkowitz E, Fuchs E, Nelson VA, Kane RA, Shippee T, Fink HA, Sylvanus T, Ouellette J, Butler M, Kane RL. Nonpharmacologic interventions for agitation and aggression in dementia. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 177. 2016 Authors' objectives To assess the efficacy, comparative effectiveness, and adverse effects of nonpharmacologic interventions for agitation and aggression

Health Technology Assessment (HTA) Database.2016

147. Sensory stimulation for persons with dementia: a review of the literature

Sensory stimulation for persons with dementia: a review of the literature 27030571 2016 06 02 2017 03 09 2017 03 09 1365-2702 25 13-14 2016 Jul Journal of clinical nursing J Clin Nurs Sensory stimulation for persons with dementia: a review of the literature. 1805-34 10.1111/jocn.13169 To provide an overview of available sensory stimulation interventions, and their effect on persons with dementia and to present theoretical and methodological characteristics of the studies included. Different (...) sensory stimulation interventions are used for persons with dementia to increase alertness, reduce agitation and improve quality of life. However, the effect of these interventions is not clear, neither are their characteristics. A systematic search and review of the literature with description of the content and an evaluation of theoretical and methodological approaches. Systematic searches in CINAHL, PubMed (Medline), The Cochrane library and PsycINFO. Studies included have been subject to quality

EvidenceUpdates2016

148. Omega-3 fatty acids for the treatment of dementia.

Omega-3 fatty acids for the treatment of dementia. BACKGROUND: Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish and plant sources are commonly considered as a promising non-medical alternative to improve brain functions and slow down the progression of dementia. This assumption is mostly based on findings of preclinical studies and epidemiological research. Resulting explanatory models aim at the role omega-3 PUFAs play in the development and integrity of the brain's neurons (...) , their protective antioxidative effect on cell membranes and potential neurochemical mechanisms directly related to Alzheimer-specific pathology. Epidemiological research also found evidence of malnutrition in people with dementia. Considering this and the fact that omega-3 PUFA cannot be synthesised by humans, omega-3 PUFAs might be a promising treatment option for dementia. OBJECTIVES: To assess the efficacy and safety of omega-3 polyunsaturated fatty acid (PUFA) supplementation for the treatment of people

Cochrane2016

149. Validation of the Spanish version of the Edinburgh feeding evaluation in dementia scale applied to institutionalized older persons with dementia: a study protocol

Validation of the Spanish version of the Edinburgh feeding evaluation in dementia scale applied to institutionalized older persons with dementia: a study protocol 27708835 2018 11 13 2054-1058 3 4 2016 10 Nursing open Nurs Open Validation of the Spanish version of the Edinburgh feeding evaluation in dementia scale applied to institutionalized older persons with dementia: a study protocol. 236-242 The aim of this study was to obtain a Spanish version of the Edinburgh Feeding Evaluation (...) in Dementia Scale version, to assess its reliability for use by medical staff and caregivers at residential care homes, to evaluate by confirmatory methods its construct validity. A further aim was to determine the criterion validity with respect to biochemical markers of malnutrition such as serum albumin, transferrin, cholesterol and lymphocytes, the body mass index and the mini nutritional assessment. Clinimetric cross-validation study. Institutionalized subjects with dementia will be observed while

Nursing open2016 Full Text: Link to full Text with Trip Pro

151. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem)

Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Bunn F, Burn A-M, Goodman C, Robinson L, Rait G, Norton S, Bennett H, Poole M, Schoeman J, Brayne C Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bunn F, Burn A-M, Goodman C, Robinson L, Rait G, Norton S, Bennett H, Poole M, Schoeman J, Brayne C. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Health Services and Delivery Research 2016; 4(8) Authors' objectives To explore the impact of dementia on access to non-dementia services and identify ways of improving

Health Technology Assessment (HTA) Database.2016

152. Diagnosis and Disruption: Population-Level Analysis Identifying Points of Care at Which Transitions Are Highest for People with Dementia and Factors That Contribute to Them

Diagnosis and Disruption: Population-Level Analysis Identifying Points of Care at Which Transitions Are Highest for People with Dementia and Factors That Contribute to Them 27000330 2016 03 22 2016 08 03 2016 03 22 1532-5415 64 3 2016 Mar Journal of the American Geriatrics Society J Am Geriatr Soc Diagnosis and Disruption: Population-Level Analysis Identifying Points of Care at Which Transitions Are Highest for People with Dementia and Factors That Contribute to Them. 569-77 10.1111/jgs.14033 (...) To examine transitions that individuals with dementia experience longitudinally and to identify points of care when transitions are highest and the factors that contribute to those transitions. Population-based 10-year retrospective cohort study from 2000 to 2011. General community. All individuals aged 65 and older newly diagnosed with dementia in British Columbia, Canada. The frequency and timing of transitions over 10 years, participant characteristics associated with greater number of transitions

EvidenceUpdates2016

153. The frontotemporal dementia-motor neuron disease continuum.

The frontotemporal dementia-motor neuron disease continuum. Early reports of cognitive and behavioural deficits in motor neuron disease might have been overlooked initially, but the concept of a frontotemporal dementia-motor neuron disease continuum has emerged during the past decade. Frontotemporal dementia-motor neuron disease is now recognised as an important dementia syndrome, which presents substantial challenges for diagnosis and management. Frontotemporal dementia, motor (...) neuron disease, and frontotemporal dementia-motor neuron disease are characterised by overlapping patterns of TAR DNA binding protein (TDP-43) pathology, while the chromosome 9 open reading frame 72 (C9orf72) repeat expansion is common across the disease spectrum. Indeed, the C9orf72 repeat expansion provides important clues to disease pathogenesis and suggests potential therapeutic targets. Variable diagnostic criteria identify motor, cognitive, and behavioural deficits, but further refinement is needed to define the clinical

Lancet2016

154. Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem)

Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Comorbidity and dementia: a mixed-method study on improving health care for people with dementia (CoDem) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found that the presence of dementia complicates the delivery of health and social care and magnifies the difficulties experienced by people with long-term conditions such as diabetes, stroke and vision impairment. {{author}} {{($index , , , , , , , , & . Frances Bunn, 1 ,* Anne-Marie Burn, 1 Claire Goodman, 1 Louise Robinson, 2 Greta Rait, 3 Sam Norton, 4 Holly Bennett, 5 Marie Poole, 2 Johan Schoeman, 6

NIHR HTA programme2016

156. Validation of the Parkinson's Disease‐Cognitive Rating Scale Applying the Movement Disorder Society Task Force Criteria for Dementia Associated with Parkinson's Disease

Validation of the Parkinson's Disease‐Cognitive Rating Scale Applying the Movement Disorder Society Task Force Criteria for Dementia Associated with Parkinson's Disease 30363353 2018 11 14 2330-1619 4 1 2017 Jan-Feb Movement disorders clinical practice Mov Disord Clin Pract Validation of the Parkinson's Disease-Cognitive Rating Scale Applying the Movement Disorder Society Task Force Criteria for Dementia Associated with Parkinson's Disease. 51-57 10.1002/mdc3.12338 The authors studied (...) the measurement properties of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) compared with Movement Disorders Society Task Force (MDS-TF) criteria for the diagnosis of dementia in patients with Parkinson's disease. The sample consisted of 223 patients who were diagnosed in accordance with the United Kingdom Parkinson's Disease Society Brain Bank who were assessed with both the MDS-TF and the PD-CRS criteria (in addition to other instruments) without the assessors' knowledge of previous results

Movement disorders clinical practice2016 Full Text: Link to full Text with Trip Pro

157. Is Dementia in Decline? Historical Trends and Future Trajectories.

Is Dementia in Decline? Historical Trends and Future Trajectories. Is Dementia in Decline? Historical Trends and Future Trajectories. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26863352 Format MeSH (...) and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Feb 11;374(6):507-9. doi: 10.1056/NEJMp1514434. Is Dementia in Decline? Historical Trends and Future Trajectories. 1 , . 1 From the Department of Global Health and Social Medicine, Harvard Medical School, Boston (D.S.J); the Department of the History of Science, Harvard University, Cambridge, MA

NEJM2016

158. Incidence of Dementia over Three Decades in the Framingham Heart Study.

Incidence of Dementia over Three Decades in the Framingham Heart Study. BACKGROUND: The prevalence of dementia is expected to soar as the average life expectancy increases, but recent estimates suggest that the age-specific incidence of dementia is declining in high-income countries. Temporal trends are best derived through continuous monitoring of a population over a long period with the use of consistent diagnostic criteria. We describe temporal trends in the incidence of dementia over three (...) decades among participants in the Framingham Heart Study. METHODS: Participants in the Framingham Heart Study have been under surveillance for incident dementia since 1975. In this analysis, which included 5205 persons 60 years of age or older, we used Cox proportional-hazards models adjusted for age and sex to determine the 5-year incidence of dementia during each of four epochs. We also explored the interactions between epoch and age, sex, apolipoprotein E ε4 status, and educational level, and we

NEJM2016

159. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study.

Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. OBJECTIVE: To determine whether higher cumulative use of benzodiazepines is associated with a higher risk of dementia or more rapid cognitive decline. DESIGN: Prospective population based cohort. SETTING: Integrated healthcare delivery system, Seattle, Washington. PARTICIPANTS: 3434 participants aged ≥ 65 without dementia at study entry. There were two rounds of recruitment (1994-96 (...) and 2000-03) followed by continuous enrollment beginning in 2004. MAIN OUTCOMES MEASURES: The cognitive abilities screening instrument (CASI) was administered every two years to screen for dementia and was used to examine cognitive trajectory. Incident dementia and Alzheimer's disease were determined with standard diagnostic criteria. Benzodiazepine exposure was defined from computerized pharmacy data and consisted of the total standardized daily doses (TSDDs) dispensed over a 10 year period (a rolling

BMJ2016 Full Text: Link to full Text with Trip Pro

160. Test Accuracy of Informant-Based Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke

Test Accuracy of Informant-Based Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke 26683423 2016 01 26 2016 06 09 2016 11 22 1524-4628 47 2 2016 Feb Stroke Stroke Test Accuracy of Informant-Based Cognitive Screening Tests for Diagnosis of Dementia and Multidomain Cognitive Impairment in Stroke. 329-35 10.1161/STROKEAHA.115.011218 Poststroke cognitive assessment can be performed using standardized questionnaires designed for family or care givers (...) . We sought to describe the test accuracy of such informant-based assessments for diagnosis of dementia/multidomain cognitive impairment in stroke. We performed a systematic review using a sensitive search strategy across multidisciplinary electronic databases. We created summary test accuracy metrics and described reporting and quality using STARDdem and Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tools, respectively. From 1432 titles, we included 11 studies. Ten papers used

EvidenceUpdates2016